US · Healthcare · Diagnostics & Research
EPS came in at -0.47 against a street estimate of -0.47 — a beat of 0.0%.
Analysts rate Natera Inc a buy (20 buy, 0 hold, 1 sell out of 21) with an average price target of $344.33.
CONFIDENT Natera exceeded expectations with 1.04M tests, 38% revenue growth to $753M, and record 34K sequential Signatera units (+56% YoY). FDA/PMDA approvals and NCCN guideline boost adoption. Raised FY26 guide by $100M midpoint to $2.85–2.91B. Q2 2026 International expansion accelerating; Japan CRC launch expected Q4 2026; EU regulatory pathway secured. Analysts probed sustainability of 34K growth, timing of ASP upside, and new product COGS drag. Management acknowledged Q2 benefited from weather recovery and near-term upside limited; emphasized long-term drivers (MolDX, guidelines, SIGNAL trials) unlock material step-ups in 2027. 2026-08-06…
Full summary in the app.
| Fund | Stake |
|---|---|
| JPMorgan Chase & Co | 9.29% |
| T. Rowe Price Associates, Inc. | 8.45% |
| BlackRock Inc | 7.41% |
| Vanguard Capital Management, LLC | 4.17% |
| Vanguard Portfolio Management, LLC | 3.92% |
| Wellington Management Company LLP | 2.80% |
| State Street Corp | 2.37% |
| Farallon Capital Management, L.L.C. | 2.23% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 NATERA, INC. – Q2 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Total revenues (6 months): $1,449.4 million (vs. $1,048.4 million in 2025, +38% YoY) • P | 2026-08-07 |
| Results announced · Q3 2026 NATERA, INC. – Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Total revenues Q2 2026: $752.8 million vs $546.6 million Q2 2025 — up 37.7% • Six-month | 2026-08-06 |
| Board / officer change · Q3 2026 NATERA, INC. (NTRA) - FORM 8-K SUMMARY OTHER NOTABLE POINTS • Board Resignation: Monica Bertagnolli resigned from the Board of Directors effective J | 2026-07-06 |
| Board / officer change · Q2 2026 NATERA, INC. (NTRA) - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held June 11, 2026 • 142,778,493 shares outstanding as of record date (Apri | 2026-06-16 |
| Board / officer change · Q2 2026 NATERA, INC. (NTRA) – 8-K SUMMARY HEADLINE NUMBERS • Board size increased from 11 to 12 members effective June 2, 2026 • New director appointment: T | 2026-06-05 |
| Quarterly report · Q1 2026 NATERA, INC. - Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Total Revenues Q1 2026: $696.6 million (up 38.7% vs Q1 2025's $501.8 million) - Product rev | 2026-05-08 |
| Proxy statement · Q2 2026 NATERA, INC. PROXY STATEMENT SUMMARY FOR RETAIL INVESTORS WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect 4 Directors – Three Class II directors | 2026-04-23 |
| Annual report FY2025 NATERA, INC. – FORM 10-K SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • 2025 Total Revenues: $2,306.1 million (vs. $1,696.9 million in 2024, + | 2026-02-27 |
Readable in the app.
| Announcement | Date |
|---|---|
| Acquired Foresight Diagnostics, cancer diagnostics company specializing in residual disease detection Natera, Inc. acquired Foresight Diagnostics Inc., a privately held cancer diagnostics company specializing in molecular residual disease (MRD) detection for B-cell lymphomas, on December 4, | 2025-12-05 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Natera Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.